The so-called ‘orphan drugs’ are intended to treat diseases so rare that sponsors are reluctant to develop them under usual marketing conditions.
The process from the discovery of a new molecule to its marketing is long (10 years in average), expensive (several tens of millions of euros) and very uncertain (among ten molecules tested, only one may have a therapeutic effect). Developing a drug intended to treat a rare disease does not allow the recovery of the capital invested for its research.
Orphan drugs may be defined as :
Drugs that are not developed by the pharmaceutical industry for economic reasons but which respond to public health need.
Actually, the indications of a drug may also be considered as ‘ orphan ‘ since a substance may be used in the treatment of a frequent disease but may not have been developed for another, more rare indication.
OTC products, short for Over-The-Counter products, are a category of medications and health remedies that can be purchased directly by consumers without a prescription. These products offer convenient and accessible solutions for various common health concerns. From pain relief and allergy medications to vitamins and skincare treatments, OTC products cater to a wide range of needs.
Oncology drugs represent a beacon of hope in the battle against cancer, offering innovative treatments and renewed possibilities for patients. The field of oncology is dedicated to understanding, diagnosing, and treating cancer, and pharmaceutical companies play a pivotal role in developing life-changing medications. These drugs are designed to target and combat cancer cells, inhibit their growth, and enhance patients’ quality of life.
Generics products have revolutionized the healthcare industry by providing high-quality, cost-effective alternatives to brand-name medications. These pharmaceuticals are bioequivalent to their brand-name counterparts, ensuring the same therapeutic effects and safety standards. Generics products offer a practical solution to the rising costs of healthcare, making essential medications more accessible to patients while maintaining uncompromised quality.
In Turkey, 16 firms produce pharmaceutical raw materials but produce 48 kinds of raw materials. In terms of pharmaceutical raw materials in Turkey it is 99% dependent on external conditions. This dependence increases with the fact that drug companies are turning to imported drugs. According to the data of the Pharmaceutical Employers’ Association, domestic production decreased from 12,646 tons in 1995 to 5,552 tons in 1999.
Nutritional supplements have become an essential part of maintaining a balanced and healthy lifestyle. In a world where hectic schedules and dietary gaps can impact our well-being, these supplements offer a convenient and effective way to bridge the nutritional deficiencies. From vitamins and minerals to specialized supplements catering to unique health needs, nutritional supplements play a vital role in ensuring that our bodies receive the essential nutrients they require.
The so-called 'orphan drugs' are intended to treat diseases so rare that sponsors are reluctant to develop them under usual marketing conditions.
The process from the discovery of a new molecule to its marketing is long (10 years in average), expensive (several tens of millions of euros) and very uncertain (among ten molecules tested, only one may have a therapeutic effect). Developing a drug intended to treat a rare disease does not allow the recovery of the capital invested for its research.
As Turk Medicines, we work to discover innovative treatments and drugs by pushing the boundaries of science.
© 2023 Turk Medicines Company – Türkiye